Search
Gilead Sciences Inc
GILDAdd to Watchlist
125.160USD
+0.110+0.09%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
155.39BMarket Cap
16.88P/E TTM
More Details of Gilead Sciences Inc Company
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Gilead Sciences Inc Info
Ticker SymbolGILD
Company nameGilead Sciences Inc
IPO dateJan 22, 1992
CEOO'Day (Daniel P)
Number of employees17600
Security typeOrdinary Share
Fiscal year-endJan 22
Address333 Lakeside Dr
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404-1147
Phone16505743000
Websitehttps://www.gilead.com/
Ticker SymbolGILD
IPO dateJan 22, 1992
CEOO'Day (Daniel P)
Company Executives of Gilead Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel P. O'Day
Mr. Daniel P. O'Day
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
FAQs
Who are the top five shareholders of Gilead Sciences Inc?
The top five shareholders of Gilead Sciences Inc are: Ms. Johanna Mercier
How many institutions hold shares of Gilead Sciences Inc (GILD)?
As of 2026Q1, 3702 institutions hold shares of Gilead Sciences Inc, with a combined market value of approximately 1.14B, accounting for 92.19% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2548741.00.
What is the biggest source of revenue for Gilead Sciences Inc?
In 2026Q1, the Biktarvy business generated the highest revenue for Gilead Sciences Inc, amounting to 14.33B and accounting for 48.68% of total revenue.
